id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-E-0022-0005,FDA,FDA-2010-E-0022,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: VIBATIV,Notice,N-Notice,2010-12-14T05:00:00Z,2010,12,2010-12-14T05:00:00Z,,2010-12-14T19:17:04Z,2010-31250,0,0,0900006480bb5ecf
FDA-2010-E-0022-0004,FDA,FDA-2010-E-0022,U.S. Patent & Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2010-06-18T04:00:00Z,2010,6,2010-06-18T04:00:00Z,,2010-10-29T01:10:40Z,,0,0,0900006480b05ab9
FDA-2010-E-0022-0003,FDA,FDA-2010-E-0022,FDA/CDER to US Patent and Trademark Office - Letter,Other,LET-Letter,2010-03-04T05:00:00Z,2010,3,2010-03-04T05:00:00Z,,2013-07-27T23:10:43Z,,0,0,0900006480ab4889
FDA-2010-E-0022-0002,FDA,FDA-2010-E-0022,"Theravance, Inc. - Patent Term Extension Application",Other,APP-Application,2010-01-12T05:00:00Z,2010,1,2010-01-12T05:00:00Z,,2013-07-27T23:04:11Z,,0,0,0900006480a7bc01
FDA-2010-E-0022-0001,FDA,FDA-2010-E-0022,U.S. Patent & Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2010-01-12T05:00:00Z,2010,1,2010-01-12T05:00:00Z,,2013-08-11T01:31:57Z,,0,0,0900006480a7baa1